Pulmonary artery pathologies in Alagille syndrome: a meta-analysis

Shi-Min Yuan

Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, China

Abstract

Alagille syndrome, caused by mutations in the gene encoding Jagged1 (JAG1), a ligand in the Notch signaling pathway, is an autosomal dominant disorder with developmental abnormalities affecting the liver, heart, eyes, face, and skeleton. The aim of the present study is to disclose the clinical features, management, and outcomes of pulmonary artery stenosis associated with Alagille syndrome. By comprehensive literature retrieval, 38 articles involving 401 patients were recruited for this study. The pertinent variables closely related to pulmonary artery stenosis in patients with Alagille syndrome were comprehensively analyzed following the PRISMA guidelines. The management of pulmonary artery pathologies, especially a severe type of pulmonary artery stenosis in Alagille syndrome, is a concerned matter. Publications of literature retrieval of recent 3 decades were the study material of this article. The pulmonary artery pathologies, especially the severe type of pulmonary artery stenosis in Alagille syndrome, warrant surgical or interventional treatments. After the procedures, the right ventricular to left ventricular pressure ratio was reduced by 25%. There were no intergroup differences in terms of recovery, reintervention, and mortality rates between interventionally and surgically treated patients. Interventional treatment is preferable due to less trauma. Surgical treatment of pulmonary artery stenosis can be performed currently with intracardiac defect repair.

Key words: Alagille syndrome, cardiac surgical procedures, pulmonary artery stenosis, stents.

Introduction

Alagille syndrome, also termed as syndromic bile duct paucity or arteriohepatic dysplasia involving the liver, heart, eyes, face, and skeleton, is an autosomal dominant disorder due to mutations of the Jagged1 (JAG1) gene of the Notch signaling pathway [1]. The estimated prevalence of Alagille syndrome is 1 in every 100,000 live births [2]. The diagnostic criteria of Alagille syndrome are cholestatic jaundice, peripheral pulmonary artery stenosis, skeletal or ocular abnormalities, typical facial features, and paucity of the bile duct on liver biopsy [3]. Cholestasis develops within the first 3 years of age with 45% of cases appearing in the first 3 months of life. The cholestasis may be associated with pruritus, episodic jaundice, hepatomegaly, xanthomas, and high cholesterol, phospholipid, and triglyceride levels [4]. Heart defects are found in 87.8% of cases [5]. The most common vascular manifestation of Alagille syndrome is pulmonary artery stenosis [6]. The pulmonary artery stenosis is usually peripheral, but sometimes central, valvular, supravalvular, or even hypoplastic or atresic [4]. Local peripheral pulmonary artery stenosis accounts for 75–90%, while diffuse pulmonary artery stenosis and pulmonary artery hypoplasia are uncommon, but capable of causing pulmonary artery hypertension [7]. Complex congenital heart defects, such as tetralogy of Fallot and pulmonary atresia, have been described in Alagille syndrome, which are proven to be associated with increased morbidity and mortality [7].

Aim

The aim of the present study is to disclose the clinical features, management, and outcomes of pulmonary artery stenosis associated with Alagille syndrome.

Material and methods

Literature retrieval from the PubMed, Google Scholar and “Baidu” Scholar was conducted for articles published from 1990 to 2021. The retrieval terms included “Alagille syndrome”, “syndromic bile duct paucity”, “arteriohepatic dysplasia”, “pulmonary artery stenosis”, “Alagille syndrome and pulmonary artery stenosis”, “Alagille syndrome and cardiac surgery”, “Alagille syndrome and interventional treatment”, “Alagille syndrome and surgical treatment”, “Alagille syndrome and pulmonary hypertension”, “Alagille syndrome and catheter-based treatment”, “Alagille syndrome and congenital heart defects”, “Alagille syndrome and morbidity”, “Alagille syndrome and mortality”.
The recruited articles included retrospective studies (n = 20) [5, 10, 13, 15–17, 20–23, 25, 26, 28, 30, 32, 36, 37, 39, 41, 42], case reports (n = 13) [3, 4, 8, 9, 12, 14, 18, 24, 27, 29, 31, 33, 35], case series (n = 2) [11, 34], medical imaging (n = 1) [19], pilot projects (n = 1) [40], and a letter to the editor (n = 1) [38]. A forest plot is shown in Figure 2.

Patient information
In total 401 patients with Alagille syndrome with pulmonary artery pathologies were included. The gender of 117 patients was described with 77 (65.8%) male and 40 (34.2%) female patients (χ² = 11.9, p < 0.001). There were 386 (96.3%) pediatrics, 11 (2.8%) adults and 4 (1.0%) fetuses. Their ages were 4.1 ±3.2 (range: 0–12.4; median: 3.5) years (n = 34), 38 ±13.9 (range: 21–54; median: 40) years (n = 5) and 29.4 ±6.2 (range: 21–34; median: 31.3) weeks of gestation (n = 4) for pediatrics, adults and fetuses, respectively.

The age at diagnosis of Alagille syndrome and (or) pulmonary artery pathology was 1.4 ±31 (range: 0–12.5; median: 0.17) years (n = 17) [4, 5, 9–12, 27, 29, 33, 35, 38] for pediatrics and adults, and at 28.57 weeks of gestation for one fetus [8] and after birth for 3 fetuses [36]. JAG1 gene mutation was detected in 129 (32.2%) patients [3, 5, 8, 25, 34, 36, 39] as well as the mother of one of the fetuses [8].

Except for the most common presenting symptoms of Alagille syndrome including jaundice and pruritus, other symptoms reported were fetal intrauterine growth retardation (n = 17) [8, 30, 36], raised spiny lesions (n = 1) [18], dyspnea and chest discomfort (n = 1) [19] and dyspnea and headache (n = 1) [35]. A systolic murmur and a systolic and diastolic murmur were heard in 12 [4, 8, 9, 11, 12, 27, 31, 33] and 1 patient [35], respectively. The 103 associated conditions of 82 patients are described in Table I.

Pulmonary artery stenosis
The laterality of pulmonary stenosis was stated for 35 patients: it was bilateral in 31 (88.6%) [3, 4, 22, 24, 26, 27, 29, 33, 35, 38], on the left in 3 (8.6%) [9, 11, 37] and on the right in 1 (2.9%) patient [37]. The severity of pulmonary artery stenosis was reported for 30 pulmonary arteries of 28 patients. It was severe/critical in 21 (69.0%) [8, 28, 29, 33, 35], moderate in 5 (17.2%) [11, 24, 27, 34, 35] and mild in 4 (13.8%) pulmonary arteries [12, 14, 24, 38].

Isolated pulmonary stenosis was found in 302 (75.3%) cases [3, 4, 5, 8, 9, 11–37, 39–42], while pulmonary stenosis with complex cardiac or vascular abnormalities was found in 86 (21.4%) cases [5, 10, 11, 16, 22, 25, 33, 36, 38, 42]. Of them, tetralogy of Fallot was present in...
71 (82.6%, 71/86) patients. In one of the reports referring to 29 cases of tetralogy of Fallot [22], the pulmonary arterial status was not indicated. In the remaining 42 patients, 28 (66.7%) had pulmonary stenosis [5, 11, 16, 25, 42], 13 (31.0%) had pulmonary atresia [16, 25, 42] and 1 (2.4%) patient had absence of the pulmonary artery [25]. In addition, pulmonary hypoplasia was present in 10 (2.5%, 10/401) patients [3, 8, 11, 30, 31, 33, 37].

| Study or subgroup | Experimental Events | Control Events | Weight (%) | Odds ratio M-H fixed, 95% CI | Odds ratio M-H fixed, 95% CI |
|-------------------|--------------------|----------------|------------|-----------------------------|-----------------------------|
| Ahn et al. 2010   | 29                 | 35             | 0          | 0                           | Not estimable               |
| Akagi et al. 2018 | 0                  | 1              | 0          | 0                           | Not estimable               |
| Albayram et al. 2002 | 0           | 1              | 0          | 0                           | Not estimable               |
| Baykan et al. 2014 | 1                  | 1              | 0          | 0                           | Not estimable               |
| Berard et al. 1998 | 5                  | 5              | 0          | 0                           | Not estimable               |
| Brodsky and Cunniff 1993 | 2                 | 2             | 0          | 3.50 [0.50, 2435.69]         |                             |
| Cambiaghi et al. 1998 | 0                 | 1              | 0          | 0                           | Not estimable               |
| Cardona et al. 1995 | 4                  | 12             | 0          | 0                           | Not estimable               |
| Cheng et al. 2004  | 0                  | 1              | 0          | 0                           | Not estimable               |
| Cunningham et al. 2013 | 3               | 3              | 0          | 0                           | Not estimable               |
| Emerick et al. 1998 | 0                 | 49             | 0          | 0                           | Not estimable               |
| Ettinger et al. 1998 | 0                | 1              | 0          | 0                           | Not estimable               |
| Gadkari et al. 2014 | 0                 | 1              | 0          | 0                           | Not estimable               |
| Gorospe Sarasua et al. 2016 | 0           | 1              | 0          | 0                           | Not estimable               |
| Kasahara et al. 2005 | 12               | 17             | 0          | 49.56 [2.69, 912.61]         |                             |
| Lee et al. 2014   | 0                  | 2              | 0          | 0                           | Not estimable               |
| Luong et al. 2020  | 29                 | 41             | 0          | 42.0 [2.69, 912.61]          |                             |
| May et al. 2012   | 0                  | 1              | 0          | 0                           | Not estimable               |
| McElhinney et al. 2002 | 32               | 46             | 0          | 23.0 [16.72, 501.27]         |                             |
| Monge et al. 2013  | 6                  | 6              | 0          | 0                           | Not estimable               |
| Mori et al. 1998  | 0                  | 1              | 0          | 0                           | Not estimable               |
| Ovaert et al. 2001 | 12                | 17             | 0          | 0                           | Not estimable               |
| Ozcan et al. 2005  | 0                  | 1              | 0          | 0                           | Not estimable               |
| Ping et al. 1999  | 3                  | 3              | 13         | 0                           | Not estimable               |
| Quick et al. 2002  | 0                  | 1              | 0          | 0                           | Not estimable               |
| Razavi et al. 2001 | 7                 | 15             | 0          | 0                           | Not estimable               |
| Saidi et al. 1998  | 1                  | 1              | 1          | 0                           | Not estimable               |
| Salem et al. 2012  | 0                  | 1              | 0          | 0                           | Not estimable               |
| Shendge et al. 2002 | 0               | 1              | 0          | 0                           | Not estimable               |
| Smithson et al. 2014 | 0            | 1              | 0          | 0                           | Not estimable               |
| Srinivasan et al. 2018 | 0             | 3              | 0          | 0                           | Not estimable               |
| Sugiyama et al. 2004 | 2                | 2              | 0          | 0                           | Not estimable               |
| Wang et al. 2004   | 0                  | 1              | 0          | 0                           | Not estimable               |
| Yang et al. 2017   | 1                  | 3              | 0          | 0                           | Not estimable               |
| Yang et al. 2020   | 0                  | 4              | 0          | 0                           | Not estimable               |
| Zhou et al. 2017   | 0                  | 6              | 0          | 0                           | Not estimable               |
| Zussman et al. 2014 | 5               | 9              | 0          | 0                           | Not estimable               |

Total (95% CI) 309 91 100.0 93.90 [18.48, 477.23]

**Figure 2. A forest plot**

**Figure 3. A graphic abstract of pulmonary artery stenosis in Alagille syndrome**

71 (82.6%, 71/86) patients. In one of the reports referring to 29 cases of tetralogy of Fallot [22], the pulmonary arterial status was not indicated. In the remaining 42 patients, 28 (66.7%) had pulmonary stenosis [5, 11, 16, 25, 42], 13 (31.0%) had pulmonary atresia [16, 25, 42] and 1 (2.4%) patient had absence of the pulmonary artery [25]. In addition, pulmonary hypoplasia was present in 10 (2.5%, 10/401) patients [3, 8, 11, 30, 31, 33, 37].
Pulmonary stenosis with single congenital or acquired heart disease was found in 13 (3.2%) cases, including atrial septal defect \( (n = 4) \) [11, 20], ventricular septal defect \( (n = 2) \) [5, 20], hypertrophic cardiomyopathy \( (n = 1) \) [5] and coarctation of the aorta \( (n = 1) \) [20].

The level of pulmonary stenosis was described for 259 patients, including peripheral in 231 (89.2%) [3–5, 9–11, 13, 15–19, 21–32, 34–38, 40], valvular in 23 (8.9%) [5, 11, 16, 25], main and peripheral in 2 (0.8%) [11, 33], valvular and infundibular in 1 (0.4%) [11], supravalvular and peripheral in 1 (0.4%) [5], and valvular and peripheral in 1 (0.4%) patient [5]. Preoperative systolic pulmonary artery pressure was 61.7 ±22.2 (range: 29–86; median: 72) mm Hg \( (n = 7) \) [3, 9, 24, 40].

There were no differences found between preoperative and postoperative right ventricular pressures (68.6 ±26.4 mm Hg vs. 73.0 ±27.0 mm Hg, \( p = 0.758 \)) or between preoperative and postoperative right ventricular pressure/left ventricular pressure ratios (0.8 ±0.3 vs. 0.6 ±0.3, \( p = 0.162 \)). A comparison of postoperative right ventricular pressure/left ventricular pressure ratios between interventionally treated patients with no residual pulmonary artery stenosis (0.59 ±0.18), interventionally treated patients with residual pulmonary artery stenosis (0.94 ±0.23) and surgically treated patients (0.37 ±0.01) did not reveal any significant differences even though the interventionally treated patients with residual pulmonary artery stenosis showed the highest ratio (Figure 3).

### Treatment and outcomes

Pulmonary artery stenosis was not intervened for 264 patients and 80 (30.3%) of them received liver transplantation [12–14, 20, 21, 28, 30, 39, 41]. The outcomes of these 80 patients were not indicated for 10 of them. Of the remaining 70 patients, 38 (54.3%) recovered, 18 (25.7%) were complicated and 14 (20%) died.

In the remaining 137 patients, 76 patients underwent 109 percutaneous interventions: 103 (94.5%) were primary interventions including 32 (31.1%) balloon angioplasty (BA) [5, 9, 29, 30, 37, 38, 42], 3 (2.9%) cutting BA [42], 1 (1.0%) high pressure BA [17], 18 (17.5%) stenting [3, 9, 11, 15, 22, 33, 35, 42] (1 of them underwent subsequent stent dilation [33], 1 (1.0%) BA + stenting [37], 2 (1.9%) percutaneous valvuloplasty [5] and 46 (44.7%) cardiovascular interventions [25], and 6 (5.5%) were reinterventions including the subsequent stent dilation. Other operations that were performed in the patients of this group were orthotopic liver transplantation in 3 patients [30], right ventricular outflow tract reconstruction and unifocalization of major aortopulmonary collateral arteries in 1 patient [5], and living donor liver transplantation with later endovascular stent for portal vein stenosis in 1 patient [29].

Surgical operation for pulmonary artery stenosis was performed in 61 patients including 57 primary operations and 4 reoperations (Table II).

The outcomes of the remaining 61 interventionally and 63 surgically treated patients from 21 reports (in

### Table I. A hundred and three associated conditions of 82 patients

| Associated condition | n (%) |
|----------------------|-------|
| Tetralogy of Fallot [5, 11, 16, 22, 38] | 47 (45.6) |
| Abdominal aorta narrowing [31] | 11 (10.7) |
| Atrial septal defect [11, 14, 20, 40] | 6 (5.8) |
| Inter-renal aortic stenosis (renovascular hypertension) [10, 34] | 6 (5.8) |
| Ventricular septal defect [8, 16, 30, 32, 40] | 5 (4.9) |
| Idiopathic descending aorta constriction [40] | 3 (2.9) |
| Aortic stenosis [14, 20] | 2 (1.9) |
| Patent foramen ovale [32, 33] | 2 (1.9) |
| s/p hepatic portocholecystostomy [19] | 2 (1.9) |
| s/p left pulmonary artery stenting [32] | 2 (1.9) |
| Abnormal pulmonary outflow tract [11] | 1 (1.0) |
| Calcified atheroma plaques and poststenotic dilation of the pulmonary arteries [19] | 1 (1.0) |
| Coarctation of the aorta [20] | 1 (1.0) |
| Granuloma annulare [40] | 1 (1.0) |
| Hypoplastic left heart syndrome [40] | 1 (1.0) |
| Multiple dermal cysts [12] | 1 (1.0) |
| s/p surgical pulmonary valvotomy [35] | 1 (1.0) |
| s/p aortic valvotomy + right ventricular outflow tract conduit insertion [38] | 1 (1.0) |
| s/p atrial septal defect closure [35] | 1 (1.0) |
| s/p liver transplantation [37] | 1 (1.0) |
| s/p modified Taussig-Bing shunt [33] | 1 (1.0) |
| s/p patent ductus arteriosus closure [35] | 1 (1.0) |
| s/p right ventricular outflow tract conduit replacement [38] | 1 (1.0) |
| s/p staged palliation of tetralogy of Fallot [24] | 1 (1.0) |
| s/p unifocalization of major aortopulmonary collateral arteries, aortopulmonary window takedown and placement of a 4-mm central shunt [24] | 1 (1.0) |
| s/p ventriculopulmonary shunt [11] | 1 (1.0) |
| Ventricular septal defect with pulmonary atresia [16] | 1 (1.0) |

s/p – status post.

### Table II. Surgical operations for pulmonary artery stenosis

| Surgical operation | n (%) |
|--------------------|-------|
| Primary operation: | 57 (93.4) |
| Patch augmentation of the left ventricular outflow tract or pulmonary artery [11, 23] | 13 (22.8) |
| Pulmonary valvuloplasty [11] | 2 (3.5) |
| Revision of bilateral branch pulmonary arteries [24] | 1 (1.8) |
| Unspecified surgical repair [22] | 41 (71.9) |
| Re-operation: | 4 (6.6) |
| Repair for shunt dehiscence at the aortic site [24] | 3 (75) |
| Later patch augmentation of the left pulmonary artery [11] | 1 (25) |
which patient outcomes were given) are shown in Table III. There were no intergroup differences in terms of recovery, reintervention and mortality rates. The complications of the interventional group patients were 3 minor complications (2 small contained vascular tears and 1 stent embolization not requiring surgery) and 1 major complication due to hemorrhage from esophageal varices which caused patient death in 1 report [42] and right pulmonary artery stent recoil that required a stent-in-stent treatment [35]. The complications of the surgical group were residual proximal branch pulmonary artery stenosis warranting a balloon angioplasty [23], shunt dehiscence occurred 3 times which were surgically repaired but finally died of septic shock [24] and another patient was complicated and died of pulmonary hypertension crisis [8].

**Discussion**

Pulmonary artery stenosis in the context of congenital heart defects, such as tetralogy of Fallot, truncus arteriosus, transposition of the great arteries, single ventricle heart disease, pulmonary atresia, or congenital rubella may be conjointly attributed to the development of pulmonary artery stenosis in Alagille syndrome [15]. The diagnosis of Alagille syndrome relies on clinical symptoms, systolic murmur best heard at the left upper sternal border and medical imaging, as well as mutations of JAG1. Alagille syndrome is reported to be caused by mutations of JAG1 in 94% of patients [43]. In this cohort of Alagille syndrome with pulmonary artery pathologies, the mutations of JAG1 accounted for 32.2%.

As it has been proved by Ahn et al. [5], pulmonary artery stenosis was the most common heart defect of Alagille syndrome accounting for 97.2% with 71.4% being peripheral pulmonary artery stenosis, followed by pulmonary stenosis at the valvular (14.3%), supravalvular pulmonary with peripheral (8.6%), and valvular with peripheral levels (5.7%).

The treatment of peripheral pulmonary artery stenosis includes surgery, BA and pulmonary artery stenting. A procedure leading to an increase in the pulmonary artery diameter by ≥ 50% or a decrease in the right ventricular to left ventricular pressure ratio by ≥ 20% is regarded as a success. Stenting was associated with a favorable outcome but without statistically surpassing that of open surgery [44]. In the present study, although the right ventricular pressures did not show a significant reduction after the procedure, the right ventricular to left ventricular pressure ratio was reduced by 25%, indicating the remarkable therapeutic effects of interventional and surgical management.

Surgical repair of the peripheral pulmonary artery is technically challenging. The techniques included reconstruction of the lobar branch pulmonary artery along with augmentation of the central and main pulmonary arteries, which resulted in 57% reduction in the right ventricle to aortic pressure ratios, and homograft patch augmentation for long-segment stenosis and surgical ostioplasty for localized ostial disease. However, it was stated that surgical repair of the peripheral pulmonary artery was disappointing with a 50–60% restenosis rate at 5 years [45]. Nevertheless, supravalvular pulmonary stenosis or bifurcation stenosis of the branch pulmonary arteries are curable to surgical repair [45]. Surgical repair of the peripheral pulmonary artery can be performed concurrently with the repair of intracardiac lesions, or simultaneous surgical repair of a pulmonary arterial lesion with palliative systemic-to-pulmonary artery shunt may also be performed [45].

Indications for liver transplantation in patients with Alagille syndrome were refractory pruritus, decompensated cirrhosis, recurrent upper gastrointestinal bleeding, and hepatopulmonary syndrome [21]. Ovaert et al. [28] described 17 patients with Alagille syndrome undergoing liver transplantation at a mean age of 3.5 years. All patients had pulmonary artery stenosis but none was symptomatic. Razavi et al. [32] pointed out that patients with Alagille syndrome and pulmonary artery lesions should attempt transcatheter stenting for pulmonary artery stenosis in patients following liver transplantation when they had failure of increase in the cardiac index by 40% or had a right ventricular pressure over half systemic pressure.

Associated intracardiac congenital heart disease, especially that found by fetal ultrasonography, and combined severe liver disease and severe heart disease were adverse predictive factors of poor survival [5]. Emerick et al. [16] reported the outcome of patients with Alagille syndrome was associated with increased mortality when there was congenital heart disease present, with an estimated survival of 40% at 20 years, compared to 80% at 20 years in its absence. Survival of Alagille patients with tetralogy of Fallot or pulmonary atresia with the ventricular septal defect was 66% and 25%, respec-

---

**Table III. A comparison of outcomes between interventional and surgical group patients**

| Group                  | Recovered | Complicated | Recurrence | Reintervention | Died |
|------------------------|-----------|-------------|------------|----------------|------|
| Intervention (n = 61)  | 40 (65.6) | 5 (8.2)*    | 2 (3.3)**  | 5 (4.9)        | 15 (24.6) |
| Surgery (n = 63)       | 48 (76.2) | 3 (4.8)***  | 2 (3.2)    | 14 (22.2)      |      |

*1 patient died and 1 patient required reintervention; **2 recurrences required reinterventions; ***2 patients required reinterventions and 2 patients died.
tively, considerably poorer than the reported survival at 10 years of 89% and 58%, respectively in patients without Alagille syndrome. The increased mortality of intervention and surgery could be attributed to: the associated cardiopulmonary malformations (tetralogy of Fallot with or without major aortopulmonary collaterals [22, 23], truncus arteriosus [23], supravalvar aortic stenosis with a gradient of 70 mm Hg [23], sinus of Valsalva aneurysm [25], Williams’ syndrome [23] and severe peripheral pulmonary artery stenosis [22, 23]), and a complex surgical procedure with a total bilirubin level of > 15 mg/dl [5].

Patient information of many reports was incomplete, and patient information in the large sample cohorts was often missing. For instance, postoperative pulmonary artery pressures were not given by all reports and a comparison of pulmonary artery pressures between pre-operation and post-operation became impossible. This aspect constituted the main drawback of this study.

Conclusions

In patients with Alagille syndrome, pulmonary artery pathologies, especially a severe type of pulmonary artery stenosis warrant surgical or interventional treatment. After the procedures, the right ventricular to left ventricular pressure ratio was reduced by 25%. There were no inter-group differences in terms of recovery, reintervention and mortality rates between interventional and surgically treated patients.

Conflict of interest

The author declares no conflict of interest.

References

1. Kamath BM, Spinner NB, Emerick KM, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004; 109: 1354-8.
2. Akagi K, Tanaka T, Baba S. Successful living donor liver transplantation after stent implantation in a patient with Alagille syndrome and severe bilateral pulmonary artery stenosis. Cardiol Young 2018; 28: 1465-7.
3. Chen H. Alagille Syndrome. In: Atlas of Genetic Diagnosis and Counseling. Springer, New York, USA 2015; 1-8.
4. Shendge H, Tullu MS, Shenoy A, et al. Alagille syndrome. Indian J Pediatr 2002; 69: 825-7.
5. Ahn KI, Yoon JK, Kim GB, et al. Alagille syndrome and a JAG1 mutation: 41 cases of experience at a single center. Korean J Pediatr 2015; 58: 392-7.
6. Kayhan A, Yashar Ilkhchou Y, Venu N, et al. Multiple abdominal vascular anomalies in a patient with Alagille syndrome. J Vasc Interv Radiol 2010; 21: 937-40.
7. Rahmone FC, Bruyère M, Tecsy M, Benhamou D. Alagille syndrome and pregnancy: anesthetic management for cesarean section. Int J Obstet Anesth 2011; 20: 355-8.
8. Albayram F, Stone K, Nagey D, et al. Alagille syndrome: prenatal diagnosis and pregnancy outcome. Fetal Diagn Ther 2002; 17: 182-4.
9. Baykan A, Argun M, Özyurt A, et al. Cutting balloon angioplasty and stent implantation for left pulmonary artery stenosis in a case with Alagille syndrome. Turk J Gastro Kals Dama 2014; 22: 642-4.
10. Bérard E, Sarles J, Triolo V, et al. Renovascular hypertension and vascular anomalies in Alagille syndrome. Pediatr Nephrol 1998; 12: 121-4.
11. Brodsky MC, Cunniff C. Ocular anomalies in the alagille syndrome (arteriohepatic dysplasia). Ophthalmology 1993; 100: 1767-74.
12. Cambiaggi S, Riva S, Ramaccioni V, et al. Stenocystoma multiplex and leuconychia in a child with Alagille syndrome. Br J Dermatol 1998; 138: 150-4.
13. Cardona J, Houssin D, Gauthier F, et al. Liver transplantation in children with Alagille syndrome: a study of twelve cases. Transplantation 1995; 60: 339-42.
14. Cheng KW, Huang JJ, Wang CH, et al. Anesthetic management of a patient with Alagille’s syndrome undergoing living donor liver transplantation without blood transfusion. Chang Gung Med J 2004; 27: 449-53.
15. Cunningham JW, McElhinney DB, Gauvreau K, et al. Outcomes after primary transcatheter therapy in infants and young children with severe bilateral peripheral pulmonary artery stenosis. Circ Cardiovasc Interv 2013; 6: 460-7.
16. Emerick KM, Rand EB, Goldmuntz E, et al. Features of alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999; 29: 822-9.
17. Ettinger LM, Hijazi ZM, Geggel RL, et al. Peripheral pulmonary artery stenosis: acute and mid-term results of high pressure balloon angioplasty. J Interven Cardiol 2010; 11: 337-44.
18. Gadkari R, Doshi B, Nayak C, et al. Unusual clinical manifestations in a case of Alagille syndrome. Pediatr Dermatol 2014; 31: 599-602.
19. Gorospe Sarasúa L, Ayala-Carbonero AM, Fernández-Méndez MÁ. Calified atherosclerosis of the pulmonary trunk, stenosis of the main pulmonary arteries, and post-stenotic dilatation of segmental pulmonary arteries in a patient with Alagille syndrome. Arch Bronconeumol 2017; 53: 73-4.
20. Kasahara M, Kiuchi T, Inomata Y, et al. Living-related liver transplantation for Alagille syndrome. Transplantation 2003; 75: 2147-50.
21. Lee CN, Tiao MM, Chen HJ, et al. Characteristics and outcome of liver transplantation in children with Alagille syndrome: a single-center experience. Pediatr Neonatol 2014; 55: 135-8.
22. Luong R, Feinstein JA, Ma M, et al. Outcomes in patients with Alagille syndrome and complex pulmonary artery disease. J Pediatr 2021; 229: 86-94.e4.
23. Mainwaring RD, Sheikh AV, Punn R, et al. Surgical outcomes for patients with pulmonary atresia/major aortopulmonary collaterals and Alagille syndrome. Eur J Cardiothorac Surg 2012; 42: 235-40.
24. May L, Hanley FL, Connolly AJ, Reddy S. Atherosclerosis causing recurrent catastrophic aortopulmonary shunt dehiscence in a patient with Alagille syndrome. Pediatr Cardiol 2013; 34: 1945-8.
25. McElhinney DB, Krantz ID, Bason L, et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002; 106: 2567-74.
26. Monge MC, Mainwaring RD, Sheikh AV, et al. Surgical reconstruction of peripheral pulmonary artery stenosis in Williams and Alagille syndromes. J Thorac Cardiovasc Surg 2013; 145: 476-81.
27. Mori Y, Kawata S, Kiso S, et al. A case of alagille syndrome – laparoscopic findings and liver biopsy views. Gastroenterol Endosc 1998; 40: 2015-20.
28. Ovaert C, Germeau C, Barrea C, et al. Elevated right ventricular pressures are not a contraindication to liver transplantation in Alagille syndrome. Transplantation 2001; 72: 345-7.
29. Ozçay F, Varan B, Tokel K, et al. Severe peripheral pulmonary artery stenosis is not a contraindication to liver transplantation in Alagille syndrome. Pediatr Transplant 2006; 10: 108-11.
30. Png K, Veyckemans F, De Kock M, et al. Hemodynamic changes in patients with Alagille’s syndrome during orthotopic liver transplantation. Anesth Analg 1999; 89: 1137-42.
31. Quek SC, Tan L, Quek ST, et al. Abdominal coarctation and Alagille syndrome. Pediatrics 2000; 106: E9.
32. Razavi RS, Baker A, Qureshi SA, et al. Hemodynamic response to continuous infusion of dobutamine in Alagille’s syndrome. Transplantation 2001; 72: 823-8.
33. Saidi AS, Kovalchin JP, Fisher DJ, et al. Balloon pulmonary valvuloplasty and stent implantation. For peripheral pulmonary artery stenosis in Alagille syndrome. Tex Heart Inst J 1998; 25: 79-82.
34. Salem JE, Bruguier E, Iserin L, et al. Hypertension and aortorenal disease in Alagille syndrome. J Hypertens 2012; 30: 1300-6.
35. Smithson S, Hall D, Trachtenberg B, et al. Treatment of cardiovascular complications of Alagille syndrome in clinical optimization for liver transplantation. Int J Cardiol 2014; 176: e37-40.
36. Srinivasan S, Howley LW, Cuneo BF, Chatfield KC. In-utero idiopathic ductal constriction: a prenatal manifestation of Alagille and Williams syndrome arteriopathy. J Perinatol 2018; 38: 1453-6.
37. Sugiyama H, Veldtman GR, Norgard G, et al. Bladed balloon angioplasty for peripheral pulmonary artery stenosis. Catheter Cardiovasc Interv 2004; 62: 71-7.
38. Wong KK, Sett SS, Human DG. Successful repair of tetralogy of Fallot with aortic valvular stenosis. Ann Thorac Surg 2004; 78: 1886.
39. Yang WH, Zhang L, Xue FS, et al. Pediatric liver transplantation for Alagille syndrome: anesthetic evaluation and perioperative management. Ann Transplant 2020; 25: e924282.
40. Yang W, Hanley FL, Chan FP, et al. Computational simulation of postoperative pulmonary flow distribution in Alagille patients with peripheral pulmonary artery stenosis. Congenit Heart Dis 2018; 13: 241-50.
41. Zhou T, Zhang J, Luo Y, et al. Clinical characteristics and outcome of liver transplantation for Alagille syndrome in children. J Digest Dis 2017; 18: 658-62.
42. Zussman M, Hirsch R, Beekman RH 3rd, Goldstein BH. Impact of percutaneous interventions for pulmonary artery stenosis in Alagille syndrome. Congenit Heart Dis 2015; 10: 310-6.
43. McDaniell R, Warthen DM, Sanchez-Lara PA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006; 79: 169-73.
44. Trant CA Jr, O’Laughlin MP, Ungerleider RM, Garson A Jr. Cost-effectiveness analysis of stents, balloon angioplasty, and surgery for the treatment of branch pulmonary artery stenosis. Pediatr Cardiol 1997; 18: 339-44.
45. Trivedi KR, Benson LN. Interventional strategies in the management of peripheral pulmonary artery stenosis. J Interv Cardiol 2003; 16: 171-88.